胆汁酸稳态范式及其与胆汁淤积性肝病的关系。
Bile acid homeostasis paradigm and its connotation with cholestatic liver diseases.
机构信息
Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing 210009, China.
Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing 210009, China; Center for Drug Screening and Pharmacodynamics Evaluation, School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China.
出版信息
Drug Discov Today. 2019 Jan;24(1):112-128. doi: 10.1016/j.drudis.2018.09.007. Epub 2018 Sep 20.
Bile acid (BA) has an important role in signal transduction, and has clinical applicability as an early biomarker for the diagnosis and prevention of cholestatic liver disease, which has a close relationship with BA homeostasis. Understanding the regulatory factors, function, and regulation of BA homeostasis under physiological conditions and in cholestatic liver diseases could provide novel therapeutic approaches for treating cholestatic liver injury. Here, we review potential biomarkers of BA, and new therapeutic approaches and the latest therapeutic drugs for cholestasis. We believe that the molecular mechanisms of cholestasis and the identification of key regulatory mechanisms of the enterohepatic circulation of BA could be pharmacologically targeted to cholestatic liver diseases.
胆汁酸 (BA) 在信号转导中具有重要作用，并且作为胆汁淤积性肝病的早期诊断和预防的生物标志物具有临床适用性，而胆汁淤积性肝病与 BA 稳态密切相关。了解生理条件下和胆汁淤积性肝病中 BA 稳态的调节因子、功能和调节，可为治疗胆汁淤积性肝损伤提供新的治疗方法。在这里，我们回顾了 BA 的潜在生物标志物，以及新的治疗方法和最新的治疗药物。我们相信，胆汁淤积的分子机制和胆汁酸肠肝循环的关键调节机制的鉴定可以成为治疗胆汁淤积性肝病的药理学靶点。
Zotero 插件